Granite Point Capital Management, L.P. Vertex Pharmaceuticals Inc Transaction History
Granite Point Capital Management, L.P.
- $0
- Q3 2023
A detailed history of Granite Point Capital Management, L.P. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Granite Point Capital Management, L.P. holds 60,000 shares of VRTX stock, worth $27.1 Million. This represents 0.91% of its overall portfolio holdings.
Number of Shares
60,000Holding current value
$27.1 Million% of portfolio
0.91%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding VRTX
# of Institutions
1,723Shares Held
222MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$12.1 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$10.4 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.61 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.33 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.06 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $116B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...